Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape

Autor:	Frida Schain, Magnus Björkholm, Xenia Gatopoulou, Christina Victoria Jones, Magnus Tambour, Nurgul Batyrbekova, Fredrik Borgsten, Kelvin Ho Man Kwok, Marta Pisini
Rok vydání:	2021
Předmět:	Male medicine.medical_specialty Registry study Improved survival Newly diagnosed Transplantation Autologous 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Internal medicine Absenteeism Outpatients Health care Humans Medicine Registries Multiple myeloma Aged Retrospective Studies Aged 80 and over Sweden Inpatients Sickness absence business.industry Hematopoietic Stem Cell Transplantation Hematology General Medicine Middle Aged medicine.disease Treatment Outcome Outpatient visits 030220 oncology & carcinogenesis Female Multiple Myeloma business Follow-Up Studies 030215 immunology
Zdroj:	European Journal of Haematology. 107:92-103
ISSN:	1600-0609 0902-4441
DOI:	10.1111/ejh.13623
Popis:	OBJECTIVES The introduction of novel drugs has significantly improved outcomes for multiple myeloma (MM) patients. This study describes survival, healthcare resource utilisation and sickness absence in association with the changing MM treatment landscape over time, focussing on patients who did not undergo autologous stem cell transplantation (ASCT). METHODS Population-based, retrospective registry study in Sweden, where 7012 non-ASCT patients diagnosed between 2001 and 2015 were stratified into diagnosis periods 2001-2005 (n = 2053), 2006-2010 (n = 2372) and 2011-2015 (n = 2587). RESULTS Median survival increased from 2.5 to 3.4 years from 2001-2005 to 2011-2015. During the first 3 years of follow-up, patients diagnosed during 2011-2015 spent 29% and 12% less time in health care (55 days; inpatient admissions and outpatient visits) than patients diagnosed during 2001-2005 (78 days) and 2006-2010 (63 days), respectively. This was associated with less inpatient and more outpatient healthcare usage. Average 3-year sickness absence (362 days) was 31% and 12% less than for patients diagnosed during 2001-2005 (522 days) and 2006-2010 (410 days), respectively. CONCLUSIONS These findings of improved survival, reduced healthcare needs and greater productivity in non-ASCT MM patients with access to improved treatment practices and novel drugs provide important real-world cost-benefit insights for the continued development and introduction of treatments for MM.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6207dff795a2568e3c6cf23af42aaef https://doi.org/10.1111/ejh.13623 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.